NASDAQ:CELC
Celcuity Inc Stock News
$16.51
-0.290 (-1.73%)
At Close: May 21, 2024
Luminex Corp (DE) (LMNX) Q2 2020 Earnings Call Transcript | The Motley Fool
06:01am, Wednesday, 05'th Aug 2020
LMNX earnings call for the period ending June 30, 2020.
QIAGEN Reports Full Results for Second Quarter and First Half Of 2020
12:00am, Tuesday, 04'th Aug 2020
QIAGEN reports full results for second quarter and first half of 2020
Celcuity Inc. Schedules Release of Second Quarter 2020 Financial Results and Conference Call
08:45pm, Friday, 24'th Jul 2020
MINNEAPOLIS, MN / ACCESSWIRE / July 24, 2020 / Celcuity Inc.
The 35 best video games you absolutely need to check out on the Nintendo Switch
06:01am, Wednesday, 22'nd Jul 2020
All of our favourite games on the Nintendo Switch
Stocks To Watch: Bank Earnings And SPAC Deals Blaze In
08:25am, Saturday, 11'th Jul 2020
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday
The
The 34 best video games you absolutely need to check out on the Nintendo Switch
05:48am, Monday, 06'th Jul 2020
34 of our favourite games on the Nintendo Switch
Celcuity Hosting Call on CELsignia Pathway Activity Test for Ovarian Cancer | | IT Business Net
12:12am, Thursday, 02'nd Jul 2020
Webcast on July 13, 2020 at 1 pm (ET) MINNEAPOLIS, MN / ACCESSWIRE / July 1, 2020 / Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company translating discoveries of new cancer sub-types
Celcuity Hosting Call on CELsignia Pathway Activity Test for Ovarian Cancer
09:30pm, Wednesday, 01'st Jul 2020
MINNEAPOLIS, MN / ACCESSWIRE / July 1, 2020 / Celcuity Inc. (CELC), a clinical-stage biotechnology company translating discoveries of new cancer sub-types into pioneering diagnostics and expanded ther
Celcuity (CELC) Gets a Buy Rating from H.C. Wainwright - Markets
10:25am, Tuesday, 23'rd Jun 2020
In a report released today, Yi Chen from H.C. Wainwright reiterated a Buy rating on Celcuity (CELC – Research Report),
Celcuity Presents Data at AACR Annual Meeting for CELsignia Pathway Activity Test for Ovarian Cancer | | IT Business Net
12:11am, Tuesday, 23'rd Jun 2020
Hyperactive c-Met and ErbB signaling detected in a sub-group of ovarian patient tumors: patient sub-group may benefit from HER2 therapy or c-Met and pan-HER combination therapy Celcuity's first t
Celcuity Presents Data at AACR Annual Meeting for CELsignia Pathway Activity Test for Ovarian Cancer
11:00pm, Monday, 22'nd Jun 2020
MINNEAPOLIS, MN / ACCESSWIRE / June 22, 2020 / Celcuity Inc. (CELC), a clinical stage biotechnology company translating discoveries of new cancer sub-types into pioneering diagnostics and expanded the
The
Global Molecular Diagnostics Partnering Terms and Agreements 2014 - 2020 - ResearchAndMarkets.com
12:00am, Tuesday, 16'th Jun 2020
The
